---
document_datetime: 2025-12-02 04:50:32
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ivemend.html
document_name: ivemend.html
version: success
processing_time: 0.452796
conversion_datetime: 2025-12-26 17:25:53.887298
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ivemend

[RSS](/en/individual-human-medicine.xml/65439)

##### Authorised

This medicine is authorised for use in the European Union

fosaprepitant Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Ivemend](#news-on)
- [More information on Ivemend](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Ivemend is a medicine for preventing nausea (feeling sick) and vomiting caused by chemotherapy cancer medicines.

It is used in adults and children from 6 months of age who are undergoing chemotherapy known to cause moderate or severe nausea and vomiting.

It contains the active substance fosaprepitant.

Expand section

Collapse section

## How is Ivemend used?

In adults, Ivemend is given as a slow infusion into a vein on the first day of chemotherapy. In children it may be given on the first day or on multiple days through a tube inserted into a large vein near the heart.

Ivemend must always be given together with other medicines that prevent nausea and vomiting, including a corticosteroid (such as dexamethasone) and a '5HT 3 antagonist' (such as ondansetron). For more information about using Ivemend, see the package leaflet or contact your doctor or pharmacist.

## How does Ivemend work?

The active substance in Ivemend, fosaprepitant, is a 'prodrug' of aprepitant. This means that it is converted to aprepitant in the body. Aprepitant is a neurokinin 1 (NK1) receptor antagonist. It stops a chemical in the body called 'substance P' from attaching to the NK1 receptors. When substance P attaches to these receptors, it causes nausea and vomiting. By blocking these receptors, Ivemend can prevent nausea and vomiting, which often happens during and after chemotherapy. Aprepitant has been authorised in the European Union (EU) as Emend since 2003.

## What benefits of Ivemend have been shown in studies?

A main study in 2,000 patients with cancer showed that Ivemend was as effective as a Emend another medicine approved for preventing nausea and vomiting. Around 72% of patients treated with either medicine did not have any nausea or vomiting over the five days after receiving chemotherapy.

## What are the risks associated with Ivemend?

The most common side effects with Ivemend (seen in between 1 and 10 patients in 100) are increased liver enzymes, headache, hiccups, constipation, dyspepsia (heartburn), loss of appetite and fatigue (weakness or tiredness). For the full list of side effects reported with Ivemend, see the package leaflet.

Ivemend must not be used at the same time as pimozide (used to treat mental illness), terfenadine and astemizole (used to treat allergy symptoms) and cisapride (used to relieve certain stomach problems). For the full list of restrictions, see the package leaflet.

## Why is Ivemend authorised in the EU?

A main study showed that Ivemend was as effective as Emend at preventing nausea and vomiting in patients undergoing chemotherapy and its side effects are considered to be manageable. The European Medicines Agency therefore decided that Ivemend's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Ivemend?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ivemend have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Ivemend are continuously monitored. Side effects reported with Ivemend are carefully evaluated and any necessary action taken to protect patients.

## Other information about Ivemend

Ivemend received a marketing authorisation valid throughout the EU on 11 January 2008.

Ivemend : EPAR - Medicine overview

English (EN) (203.44 KB - PDF)

**First published:** 12/08/2009

**Last updated:** 08/05/2018

[View](/en/documents/overview/ivemend-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-189)

български (BG) (135.56 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

08/05/2018

[View](/bg/documents/overview/ivemend-epar-medicine-overview_bg.pdf)

español (ES) (96.25 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

08/05/2018

[View](/es/documents/overview/ivemend-epar-medicine-overview_es.pdf)

čeština (CS) (119.53 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

08/05/2018

[View](/cs/documents/overview/ivemend-epar-medicine-overview_cs.pdf)

dansk (DA) (94.9 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

08/05/2018

[View](/da/documents/overview/ivemend-epar-medicine-overview_da.pdf)

Deutsch (DE) (96.23 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

08/05/2018

[View](/de/documents/overview/ivemend-epar-medicine-overview_de.pdf)

eesti keel (ET) (94.36 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

08/05/2018

[View](/et/documents/overview/ivemend-epar-medicine-overview_et.pdf)

ελληνικά (EL) (141.63 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

08/05/2018

[View](/el/documents/overview/ivemend-epar-medicine-overview_el.pdf)

français (FR) (96.29 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

08/05/2018

[View](/fr/documents/overview/ivemend-epar-medicine-overview_fr.pdf)

hrvatski (HR) (114.67 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

08/05/2018

[View](/hr/documents/overview/ivemend-epar-medicine-overview_hr.pdf)

italiano (IT) (95.56 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

08/05/2018

[View](/it/documents/overview/ivemend-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (116.92 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

08/05/2018

[View](/lv/documents/overview/ivemend-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (117.44 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

08/05/2018

[View](/lt/documents/overview/ivemend-epar-medicine-overview_lt.pdf)

magyar (HU) (113.64 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

08/05/2018

[View](/hu/documents/overview/ivemend-epar-medicine-overview_hu.pdf)

Malti (MT) (131.92 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

08/05/2018

[View](/mt/documents/overview/ivemend-epar-medicine-overview_mt.pdf)

Nederlands (NL) (183.53 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

08/05/2018

[View](/nl/documents/overview/ivemend-epar-medicine-overview_nl.pdf)

polski (PL) (120.1 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

08/05/2018

[View](/pl/documents/overview/ivemend-epar-medicine-overview_pl.pdf)

português (PT) (96.1 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

08/05/2018

[View](/pt/documents/overview/ivemend-epar-medicine-overview_pt.pdf)

română (RO) (117.33 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

08/05/2018

[View](/ro/documents/overview/ivemend-epar-medicine-overview_ro.pdf)

slovenčina (SK) (116.74 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

08/05/2018

[View](/sk/documents/overview/ivemend-epar-medicine-overview_sk.pdf)

slovenščina (SL) (112.96 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

08/05/2018

[View](/sl/documents/overview/ivemend-epar-medicine-overview_sl.pdf)

Suomi (FI) (95.1 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

08/05/2018

[View](/fi/documents/overview/ivemend-epar-medicine-overview_fi.pdf)

svenska (SV) (95.46 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

08/05/2018

[View](/sv/documents/overview/ivemend-epar-medicine-overview_sv.pdf)

## Product information

Ivemend : EPAR - Product Information

English (EN) (363.91 KB - PDF)

**First published:** 07/08/2009

**Last updated:** 05/11/2025

[View](/en/documents/product-information/ivemend-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-823)

български (BG) (337.14 KB - PDF)

**First published:**

07/08/2009

**Last updated:**

05/11/2025

[View](/bg/documents/product-information/ivemend-epar-product-information_bg.pdf)

español (ES) (380.9 KB - PDF)

**First published:**

07/08/2009

**Last updated:**

05/11/2025

[View](/es/documents/product-information/ivemend-epar-product-information_es.pdf)

čeština (CS) (384.18 KB - PDF)

**First published:**

07/08/2009

**Last updated:**

05/11/2025

[View](/cs/documents/product-information/ivemend-epar-product-information_cs.pdf)

dansk (DA) (378.1 KB - PDF)

**First published:**

07/08/2009

**Last updated:**

05/11/2025

[View](/da/documents/product-information/ivemend-epar-product-information_da.pdf)

Deutsch (DE) (485.77 KB - PDF)

**First published:**

07/08/2009

**Last updated:**

05/11/2025

[View](/de/documents/product-information/ivemend-epar-product-information_de.pdf)

eesti keel (ET) (380.07 KB - PDF)

**First published:**

07/08/2009

**Last updated:**

05/11/2025

[View](/et/documents/product-information/ivemend-epar-product-information_et.pdf)

ελληνικά (EL) (474.58 KB - PDF)

**First published:**

07/08/2009

**Last updated:**

05/11/2025

[View](/el/documents/product-information/ivemend-epar-product-information_el.pdf)

français (FR) (418.8 KB - PDF)

**First published:**

07/08/2009

**Last updated:**

05/11/2025

[View](/fr/documents/product-information/ivemend-epar-product-information_fr.pdf)

hrvatski (HR) (377.35 KB - PDF)

**First published:**

07/08/2009

**Last updated:**

05/11/2025

[View](/hr/documents/product-information/ivemend-epar-product-information_hr.pdf)

íslenska (IS) (397.35 KB - PDF)

**First published:**

07/08/2009

**Last updated:**

05/11/2025

[View](/is/documents/product-information/ivemend-epar-product-information_is.pdf)

italiano (IT) (408.12 KB - PDF)

**First published:**

07/08/2009

**Last updated:**

05/11/2025

[View](/it/documents/product-information/ivemend-epar-product-information_it.pdf)

latviešu valoda (LV) (359.55 KB - PDF)

**First published:**

07/08/2009

**Last updated:**

05/11/2025

[View](/lv/documents/product-information/ivemend-epar-product-information_lv.pdf)

lietuvių kalba (LT) (382.72 KB - PDF)

**First published:**

07/08/2009

**Last updated:**

05/11/2025

[View](/lt/documents/product-information/ivemend-epar-product-information_lt.pdf)

magyar (HU) (423.79 KB - PDF)

**First published:**

07/08/2009

**Last updated:**

05/11/2025

[View](/hu/documents/product-information/ivemend-epar-product-information_hu.pdf)

Malti (MT) (399.67 KB - PDF)

**First published:**

07/08/2009

**Last updated:**

05/11/2025

[View](/mt/documents/product-information/ivemend-epar-product-information_mt.pdf)

Nederlands (NL) (393.48 KB - PDF)

**First published:**

07/08/2009

**Last updated:**

05/11/2025

[View](/nl/documents/product-information/ivemend-epar-product-information_nl.pdf)

norsk (NO) (356.98 KB - PDF)

**First published:**

07/08/2009

**Last updated:**

05/11/2025

[View](/no/documents/product-information/ivemend-epar-product-information_no.pdf)

polski (PL) (402.87 KB - PDF)

**First published:**

07/08/2009

**Last updated:**

05/11/2025

[View](/pl/documents/product-information/ivemend-epar-product-information_pl.pdf)

português (PT) (386.75 KB - PDF)

**First published:**

07/08/2009

**Last updated:**

05/11/2025

[View](/pt/documents/product-information/ivemend-epar-product-information_pt.pdf)

română (RO) (386.04 KB - PDF)

**First published:**

07/08/2009

**Last updated:**

05/11/2025

[View](/ro/documents/product-information/ivemend-epar-product-information_ro.pdf)

slovenčina (SK) (393.83 KB - PDF)

**First published:**

07/08/2009

**Last updated:**

05/11/2025

[View](/sk/documents/product-information/ivemend-epar-product-information_sk.pdf)

slovenščina (SL) (377.86 KB - PDF)

**First published:**

07/08/2009

**Last updated:**

05/11/2025

[View](/sl/documents/product-information/ivemend-epar-product-information_sl.pdf)

Suomi (FI) (392.96 KB - PDF)

**First published:**

07/08/2009

**Last updated:**

05/11/2025

[View](/fi/documents/product-information/ivemend-epar-product-information_fi.pdf)

svenska (SV) (369.14 KB - PDF)

**First published:**

07/08/2009

**Last updated:**

05/11/2025

[View](/sv/documents/product-information/ivemend-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000307871 03/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Ivemend : EPAR - All Authorised presentations

English (EN) (9.94 KB - PDF)

**First published:** 05/02/2008

**Last updated:** 10/07/2013

[View](/en/documents/all-authorised-presentations/ivemend-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-587)

български (BG) (39.12 KB - PDF)

**First published:**

05/02/2008

**Last updated:**

10/07/2013

[View](/bg/documents/all-authorised-presentations/ivemend-epar-all-authorised-presentations_bg.pdf)

español (ES) (10.72 KB - PDF)

**First published:**

05/02/2008

**Last updated:**

10/07/2013

[View](/es/documents/all-authorised-presentations/ivemend-epar-all-authorised-presentations_es.pdf)

čeština (CS) (39.76 KB - PDF)

**First published:**

05/02/2008

**Last updated:**

10/07/2013

[View](/cs/documents/all-authorised-presentations/ivemend-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (9.36 KB - PDF)

**First published:**

05/02/2008

**Last updated:**

10/07/2013

[View](/da/documents/all-authorised-presentations/ivemend-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (9.38 KB - PDF)

**First published:**

05/02/2008

**Last updated:**

10/07/2013

[View](/de/documents/all-authorised-presentations/ivemend-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (8.97 KB - PDF)

**First published:**

05/02/2008

**Last updated:**

10/07/2013

[View](/et/documents/all-authorised-presentations/ivemend-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (39.53 KB - PDF)

**First published:**

05/02/2008

**Last updated:**

10/07/2013

[View](/el/documents/all-authorised-presentations/ivemend-epar-all-authorised-presentations_el.pdf)

français (FR) (9.02 KB - PDF)

**First published:**

05/02/2008

**Last updated:**

10/07/2013

[View](/fr/documents/all-authorised-presentations/ivemend-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (30.43 KB - PDF)

**First published:**

05/02/2008

**Last updated:**

10/07/2013

[View](/hr/documents/all-authorised-presentations/ivemend-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (9.33 KB - PDF)

**First published:**

05/02/2008

**Last updated:**

10/07/2013

[View](/is/documents/all-authorised-presentations/ivemend-epar-all-authorised-presentations_is.pdf)

italiano (IT) (8.93 KB - PDF)

**First published:**

05/02/2008

**Last updated:**

10/07/2013

[View](/it/documents/all-authorised-presentations/ivemend-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (37.91 KB - PDF)

**First published:**

05/02/2008

**Last updated:**

10/07/2013

[View](/lv/documents/all-authorised-presentations/ivemend-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (37.81 KB - PDF)

**First published:**

05/02/2008

**Last updated:**

10/07/2013

[View](/lt/documents/all-authorised-presentations/ivemend-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (22.73 KB - PDF)

**First published:**

05/02/2008

**Last updated:**

10/07/2013

[View](/hu/documents/all-authorised-presentations/ivemend-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (38.05 KB - PDF)

**First published:**

05/02/2008

**Last updated:**

10/07/2013

[View](/mt/documents/all-authorised-presentations/ivemend-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (9.04 KB - PDF)

**First published:**

05/02/2008

**Last updated:**

10/07/2013

[View](/nl/documents/all-authorised-presentations/ivemend-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (9.66 KB - PDF)

**First published:**

05/02/2008

**Last updated:**

10/07/2013

[View](/no/documents/all-authorised-presentations/ivemend-epar-all-authorised-presentations_no.pdf)

polski (PL) (38.34 KB - PDF)

**First published:**

05/02/2008

**Last updated:**

10/07/2013

[View](/pl/documents/all-authorised-presentations/ivemend-epar-all-authorised-presentations_pl.pdf)

português (PT) (9.34 KB - PDF)

**First published:**

05/02/2008

**Last updated:**

10/07/2013

[View](/pt/documents/all-authorised-presentations/ivemend-epar-all-authorised-presentations_pt.pdf)

română (RO) (37.03 KB - PDF)

**First published:**

05/02/2008

**Last updated:**

10/07/2013

[View](/ro/documents/all-authorised-presentations/ivemend-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (38.48 KB - PDF)

**First published:**

05/02/2008

**Last updated:**

10/07/2013

[View](/sk/documents/all-authorised-presentations/ivemend-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (21.52 KB - PDF)

**First published:**

05/02/2008

**Last updated:**

10/07/2013

[View](/sl/documents/all-authorised-presentations/ivemend-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (8.94 KB - PDF)

**First published:**

05/02/2008

**Last updated:**

10/07/2013

[View](/fi/documents/all-authorised-presentations/ivemend-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (9.26 KB - PDF)

**First published:**

05/02/2008

**Last updated:**

10/07/2013

[View](/sv/documents/all-authorised-presentations/ivemend-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Ivemend Active substance fosaprepitant International non-proprietary name (INN) or common name fosaprepitant Therapeutic area (MeSH)

- Vomiting
- Cancer

Anatomical therapeutic chemical (ATC) code A04AD12

### Pharmacotherapeutic group

Antiemetics and antinauseants

### Therapeutic indication

Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older.

Ivemend 150 mg is given as part of a combination therapy.

## Authorisation details

EMA product number EMEA/H/C/000743 Marketing authorisation holder

Merck Sharp &amp; Dohme B.V.

Waarderweg 39

Marketing authorisation issued 11/01/2008 Revision 27

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Ivemend : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (141.59 KB - PDF)

**First published:** 22/04/2025

**Last updated:** 05/11/2025

[View](/en/documents/procedural-steps-after/ivemend-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Ivemend : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (193.09 KB - PDF)

**First published:** 12/08/2009

**Last updated:** 22/04/2025

[View](/en/documents/procedural-steps-after/ivemend-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Ivemend-H-C-743-II-0037 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/219267/2018

English (EN) (3.88 MB - PDF)

**First published:** 08/05/2018

**Last updated:** 08/05/2018

[View](/en/documents/variation-report/ivemend-h-c-743-ii-0037-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Ivemend

Adopted

Reference Number: EMA/CHMP/171802/2018

English (EN) (103.2 KB - PDF)

**First published:** 23/03/2018

**Last updated:** 23/03/2018

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ivemend_en.pdf)

Ivemend-H-C-743-P46-025/026 : EPAR - Assessment report

Adopted

Reference Number: EMA/CHMP/547330/2017

English (EN) (401.42 KB - PDF)

**First published:** 26/09/2017

**Last updated:** 26/09/2017

[View](/en/documents/variation-report/ivemend-h-c-743-p46-025026-epar-assessment-report_en.pdf)

Ivemend : EPAR - Paediatric investigation plan compliance statement

English (EN) (68.8 KB - PDF)

**First published:** 06/02/2017

**Last updated:** 06/02/2017

[View](/en/documents/pip-compliance/ivemend-epar-paediatric-investigation-plan-compliance-statement_en.pdf)

Ivemend-H-C-PSUSA-1471-201603: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

English (EN) (65.37 KB - PDF)

**First published:** 06/02/2017

**Last updated:** 06/02/2017

[View](/en/documents/scientific-conclusion/ivemend-h-c-psusa-1471-201603-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Ivemend-H-C-743-P46-0024.1 : EPAR - Assessment Report

Adopted

Reference Number: EMA/294881/2015

English (EN) (1.62 MB - PDF)

**First published:** 08/05/2015

**Last updated:** 08/05/2015

[View](/en/documents/variation-report/ivemend-h-c-743-p46-00241-epar-assessment-report_en.pdf)

Ivemend-H-C-527-PSUV-0022: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/11999/2014

English (EN) (73.51 KB - PDF)

**First published:** 13/01/2014

**Last updated:** 13/01/2014

[View](/en/documents/scientific-conclusion/ivemend-h-c-527-psuv-0022-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Ivemend-H-C-743-X-0006 : EPAR - Assessment Report - Extension

Adopted

English (EN) (594.15 KB - PDF)

**First published:** 24/09/2010

**Last updated:** 24/09/2010

[View](/en/documents/variation-report/ivemend-h-c-743-x-0006-epar-assessment-report-extension_en.pdf)

## Initial marketing authorisation documents

Ivemend : EPAR - Public assessment report

English (EN) (498.08 KB - PDF)

**First published:** 05/02/2008

**Last updated:** 05/02/2008

[View](/en/documents/assessment-report/ivemend-epar-public-assessment-report_en.pdf)

#### News on Ivemend

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 March 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-march-2018) 23/03/2018

#### More information on Ivemend

- [EMEA-000406-PIP01-08-M04 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000406-pip01-08-m04)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)
- [Paediatrics](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A65)

**This page was last updated on** 05/11/2025

## Share this page

[Back to top](#main-content)